Render Target: STATIC
Render Timestamp: 2024-11-22T12:06:37.368Z
Commit: 5c4accf06eb7154018ba3f54329c7590f97f534a
XML generation date: 2024-09-30 02:00:03.570
Product last modified at: 2024-10-30T13:00:34.934Z
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

RPL22 (F1J4Y) Rabbit mAb #54055

Filter:
  • WB

    Supporting Data

    REACTIVITY H M R Mk
    SENSITIVITY Endogenous
    MW (kDa) 15
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    Species Cross-Reactivity Key:
    • H-Human 
    • M-Mouse 
    • R-Rat 
    • Mk-Monkey 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    RPL22 (F1J4Y) Rabbit mAb recognizes endogenous levels of total RPL22 protein. This antibody does not cross-react with RPL22L1 protein.

    Species Reactivity:

    Human, Mouse, Rat, Monkey

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ile70 of human RPL22 protein.

    Background

    RPL22 and RPL22L1 are highly related 60S ribosomal protein paralogs. They both function in protein synthesis and play distinct and sometimes antagonistic roles in hematopoietic stem cell development through p53 (1-3). RPL22 can directly regulate RPL22L1 expression by binding to an internal hairpin on the RPL22L1 mRNA. RPL22 has also been shown to interact with mRNAs for telomerase, histone H1, and EBER1, a noncoding RNA from the Epstein-Barr virus (EBV) (4-6). Both RPL22 and RPL22L1 have been shown to play roles in carcinogenesis. Inactivation of RPL22 can occur in acute lymphoblastic leukemias, which results in increased expression of Lin28B (2). Low expression of RPL22 has also been described in lung and gastric cancers (7,8). RPL22L1 has been implicated in prostate cancer, and its induction is associated with poor prognosis in colorectal cancer (9,10).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.